Xilio Therapeutics, Inc. (XLO)
XLO Stock Price Chart
Explore Xilio Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze XLO price movements and trends.
XLO Company Profile
Discover essential business fundamentals and corporate details for Xilio Therapeutics, Inc. (XLO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Oct 2021
Employees
64.00
Website
https://www.xiliotx.comCEO
Rene Russo BCPS,
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
XLO Financial Timeline
Browse a chronological timeline of Xilio Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 9 Mar 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.03.
Earnings released on 14 Aug 2025
EPS came in at -$0.16 falling short of the estimated -$0.08 by -100.00%, while revenue for the quarter reached $8.08M , missing expectations by -1.53%.
Earnings released on 8 May 2025
EPS came in at -$0.18 falling short of the estimated $0.10 by -280.00%, while revenue for the quarter reached $2.93M , missing expectations by -87.37%.
Earnings released on 11 Mar 2025
EPS came in at -$0.20 surpassing the estimated -$0.22 by +9.09%, while revenue for the quarter reached $1.72M , missing expectations by -92.57%.
Earnings released on 7 Nov 2024
EPS came in at -$0.22 surpassing the estimated -$0.25 by +12.00%, while revenue for the quarter reached $2.26M , missing expectations by -31.42%.
Earnings released on 8 Aug 2024
EPS came in at -$0.24 falling short of the estimated -$0.23 by -4.35%, while revenue for the quarter reached $2.36M , missing expectations by -92.14%.
Earnings released on 14 May 2024
EPS came in at -$0.59 falling short of the estimated -$0.30 by -96.67%.
Earnings released on 1 Apr 2024
EPS came in at -$0.64 falling short of the estimated -$0.62 by -3.23%, while revenue for the quarter reached $2.90M , missing expectations by -90.33%.
Earnings released on 9 Nov 2023
EPS came in at -$0.78 .
Earnings released on 9 Nov 2023
EPS came in at -$0.61 surpassing the estimated -$0.76 by +19.74%.
Earnings released on 9 Nov 2023
EPS came in at -$0.70 .
Earnings released on 9 Nov 2023
EPS came in at -$0.79 .
Earnings released on 9 Nov 2022
EPS came in at -$0.72 surpassing the estimated -$0.89 by +19.10%.
Earnings released on 9 Aug 2022
EPS came in at -$0.90 falling short of the estimated -$0.78 by -15.38%.
Earnings released on 12 May 2022
EPS came in at -$0.78 surpassing the estimated -$1.00 by +22.00%.
Earnings released on 1 Mar 2022
EPS came in at -$0.98 falling short of the estimated -$0.94 by -4.26%.
Earnings released on 2 Dec 2021
EPS came in at -$21.27 falling short of the estimated -$1.60 by -1.23K%.
Earnings released on 30 Jun 2021
EPS came in at -$0.87 .
Earnings released on 31 Mar 2021
EPS came in at -$0.63 .
Earnings released on 31 Dec 2020
EPS came in at -$0.78 .
Earnings released on 30 Sept 2020
EPS came in at -$0.56 .
XLO Stock Performance
Access detailed XLO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.